Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: IPILIMUMAB, . Treffer: 8
2023
Ascierto, PA; Mandalà, M; Ferrucci, PF; Guidoboni, M; Rutkowski, P; Ferraresi, V; Arance, A; Guida, M; Maiello, E; Gogas, H; Richtig, E; Fierro, MT; Lebbè, C; Helgadottir, H; Queirolo, P; Spagnolo, F; Tucci, M; Del, Vecchio, M; Gonzales, Cao, M; Minisini, AM; De, Placido, S; Sanmamed, MF; Mallardo, D; Curvietto, M; Melero, I; Palmieri, G; Grimaldi, AM; Giannarelli, D; Dummer, R; Chiarion, Sileni, V
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol. 2023; 41(2): 212-221.
Doi: 10.1200/JCO.21.02961
Web of Science
PubMed
FullText
FullText_MUG
Mutz-Rabl, CG; Koelblinger, P; Koch, L
Immunotherapy for metastatic melanoma-from little benefit to first-line treatment
MEMO-MAG EUR MED ONC. 2023;
Doi: 10.1007/s12254-023-00881-6
Web of Science
FullText
FullText_MUG
2021
Absenger, G; Terbuch, A
Unresectable pleural mesothelioma-hope or still an unmet medical need?
MEMO-MAG EUR MED ONC. 2021;
Doi: 10.1007/s12254-021-00727-z
Web of Science
FullText
FullText_MUG
2018
Carlino, MS; Long, GV; Schadendorf, D; Robert, C; Ribas, A; Richtig, E; Nyakas, M; Caglevic, C; Tarhini, A; Blank, C; Hoeller, C; Bar-Sela, G; Barrow, C; Wolter, P; Zhou, H; Emancipator, K; Jensen, EH; Ebbinghaus, S; Ibrahim, N; Daud, A
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
EUR J CANCER. 2018; 101(3): 236-243.
Doi: 10.1016/j.ejca.2018.06.034
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Richtig, G; Hoeller, C; Wolf, M; Wolf, I; Rainer, BM; Schulter, G; Richtig, M; Grübler, MR; Gappmayer, A; Haidn, T; Kofler, J; Huegel, R; Lange-Asschenfeldt, B; Pichler, M; Pilz, S; Heinemann, A; Richtig, E
Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.
PLoS One. 2018; 13(10):e0204729-e0204729
Doi: 10.1371/journal.pone.0204729
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2017
Petrella, TM; Robert, C; Richtig, E; Miller, WH; Masucci, GV; Walpole, E; Lebbe, C; Steven, N; Middleton, MR; Hille, D; Zhou, W; Ibrahim, N; Cebon, J
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
EUR J CANCER. 2017; 86(5): 115-124.
Doi: 10.1016/j.ejca.2017.08.032
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Richtig, G; Aigelsreiter, A; Kashofer, K; Talakic, E; Kupsa, R; Schaider, H; Richtig, E
Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options.
Case Rep Oncol. 2016; 9(3):543-546
Doi: 10.1159/000449125
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
Robert, C; Schachter, J; Long, GV; Arance, A; Grob, JJ; Mortier, L; Daud, A; Carlino, MS; McNeil, C; Lotem, M; Larkin, J; Lorigan, P; Neyns, B; Blank, CU; Hamid, O; Mateus, C; Shapira-Frommer, R; Kosh, M; Zhou, H; Ibrahim, N; Ebbinghaus, S; Ribas, A; KEYNOTE-006 investigators
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015; 372(26):2521-2532
Doi: 10.1056/NEJMoa1503093
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG